Navigation Links
Use of Sequenom's MassARRAY System Leads to Significant Scientific,Advances in Understanding Cancer, Diabetes and Drug-Resistant,Malaria

fe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with the Company's technologies, market acceptance of and demand for the Company's products, reliance upon the collaborative efforts of others, product development and commercialization, and other risks detailed from time to time in the Company's SEC reports, including the Company's Annual Report on Form 10-K for the year ended December 31, 2005 and subsequent periodic reports. These forward-looking statements are based on current information that is likely to change and speak only as of the date hereof. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and Sequenom undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

Contact

Company Contact
Sequenom, Inc.
John Sharp, VP, Finance, 858-202-9032
or
Investor Relations Contact
Lippert/Heilshorn & Associates
Zachary Bryant, zbryant@lhai.com
Jody Cain, jcain@lhai.com
310-691-7100


'"/>




Page: 1 2 3

Related medicine technology :

1. When Volume Matters, Immunoassay Systems Deliver
2. Genetic Analysis Systems Enter the Clinical Mainstream
3. New Quality Control Systems for Every Laboratory Application
4. Immunoassay Systems - Your Laboratory Workhorse
5. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
6. Researchers Discover Method for Identifying How Cancer Evades the Immune System
7. Next Safety, Inc.s Innovative Drug Delivery System Will Replace Cigarettes and Significantly Advance Pulmonary Medication Delivery
8. Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
9. Research Indicates Gerons Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System
10. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
11. SPIRIT Clinical Data Reaffirm Strength of Taxus and Promus Drug-Eluting Coronary Stent Systems
Post Your Comments:
(Date:10/8/2008)...ornell University Food Scientists Expand Testing U...tivity Assay, PORTLAND, Maine, Oct. 8 /PRNewswire...today with the release of results from a new study...er commonly consumed,fruits like apples, bananas, ...ing the Cellular Antioxidant Activity (CAA) assay....
(Date:10/8/2008)...N, France, Oct. 8 /- Vical Incorporat...linical data and new nonclinical data,demonstratin...broadly,applicable in DNA- and protein-based infec...ccines. Alain P. Rolland, Pharm.D., Ph.D., Vical,s...l present the data today,Wednesday, October 8, at...
(Date:10/7/2008)...NT, Mich., Oct. 7 /- McLaren Health C...ring some of the world,s leading medical,minds to ... breast and,gastrointestinal cancer treatments. Th...CI, was organized by McLaren,s Sukamal Saha, M.D.,...n sentinel node mapping for,colorectal cancer has ...
(Date:10/7/2008)...ults of FLEXX Trial Presented at the Osteoarthriti...ress, PARSIPPANY, N.J., Oct. 7 /- Fe...lts from the FLEXX Trial of Osteoarthritis of the,...ate), a highly pure,non-avian high molecular weigh... is superior to intra-articular saline (IA-saline)...
Breaking Medicine Technology:Wild Blueberries Take Top Spot in New Antioxidant Research Study 2Wild Blueberries Take Top Spot in New Antioxidant Research Study 3Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 2Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 3Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 5News Media Advisory: World's Leading Surgical Oncologists to Gather at McLaren Regional Medical Center to Present Latest Work on Breast, Gastrointestinal Cancer Treatments 2Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period 2Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period 3Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period 4IDM Pharma Announces Upcoming Clinical Data Presentations 674 1IDM Pharma Announces Upcoming Clinical Data Presentations 674 2IDM Pharma Announces Upcoming Clinical Data Presentations 674 3IDM Pharma Announces Upcoming Clinical Data Presentations 674 4Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BIOCOM Investor Conference 2007 1521 1Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BIOCOM Investor Conference 2007 1521 2ASA San Diego Offers Resources and Information to Families with Autism in Wake of Fires 4675 1ASA San Diego Offers Resources and Information to Families with Autism in Wake of Fires 4675 2Kosan to Reacquire Epothilone Program From Roche 1518 1Kosan to Reacquire Epothilone Program From Roche 1518 2Kosan to Reacquire Epothilone Program From Roche 1518 3Kosan to Reacquire Epothilone Program From Roche 1518 4
...linical study of,HGS-ETR1 -, ROCKVILLE, Md., April...ciences, Inc. today reported that clinical and pre...g that its TRAIL receptor,antibodies, HGS-ETR1 (ma...icant potential for use in the treatment of a broa...d HGS-ETR2 could offer novel, highly,targeted ther...
...llaGenex,Pharmaceuticals, Inc. (NASDAQ:CGPI) today... of the Journal of the American Academy,of Dermato...trials,demonstrated the efficacy and safety of an... doxycycline, USP capsules) for the,treatment of r...tablish the first important body of evidence suppo...
Other Medicine Technology:Human Genome Sciences Reports Growing Evidence That Its TRAIL,Receptor Antibodies Have Significant Potential in the Treatment of,a Broad Range of Cancers 2Human Genome Sciences Reports Growing Evidence That Its TRAIL,Receptor Antibodies Have Significant Potential in the Treatment of,a Broad Range of Cancers 3Human Genome Sciences Reports Growing Evidence That Its TRAIL,Receptor Antibodies Have Significant Potential in the Treatment of,a Broad Range of Cancers 4Human Genome Sciences Reports Growing Evidence That Its TRAIL,Receptor Antibodies Have Significant Potential in the Treatment of,a Broad Range of Cancers 5Evaluating the Efficacy and Safety of Once-Daily Anti-Inflammatory,Dose Doxycycline for the Treatment of Rosacea 2Evaluating the Efficacy and Safety of Once-Daily Anti-Inflammatory,Dose Doxycycline for the Treatment of Rosacea 3Evaluating the Efficacy and Safety of Once-Daily Anti-Inflammatory,Dose Doxycycline for the Treatment of Rosacea 4
(Date:10/10/2008)...e testing is often on those already on drugs, some..., FRIDAY, Oct. 10 (HealthDay News) -- A new study ... Clostridium difficile ( C. difficile ) infections...rchers with McGill University and the Jewish Gener...senior citizens who acquired C. difficile infect...
(Date:10/10/2008)...MONTVALE, N.J., Oct. 10 /PRNewswire-FirstCall/ -- ...s that it has appointed William,(Bill) Federici, 4...to five,members., Mr. Federici joined West Pharma...ncial Officer in August of 2003. Under his financi... grown to more than $1.0 billion from,$300 million...
(Date:10/10/2008)...RICHMOND, Va., Oct. 10 /PRNewswire/ -- Do you thin...Can,t get around town? Attend the October,17 open ...e Blind and,Vision Impaired, and see how instructo...o lead productive, fulfilling lives through non-vi..., located at 401 Azalea Avenue, is holding an open...
(Date:10/10/2008)... Upon the completion of a hig...vision of CDM Media proudly announces their next b...ief information technology executives in healthcar...it will launch May 10-12, 2009 at the Four Seasons... Honolulu, HI (PRWEB) October 11, 2008 -- Upon ...
Breaking Medicine News(10 mins):Health News:Antibiotics May Not Cause Diarrheal Bacteria 2Health News:Synvista Therapeutics Appoints William Federici to its Board of Directors 2Health News:Synvista Therapeutics Appoints William Federici to its Board of Directors 3Health News:Virginia Rehabilitation Center for the Blind and Vision Impaired Celebrates Opening of New Student Dormitory 2Health News:CIO Healthcare Summit Announces Dates and VIP Delegates 2
...at awards and accomplishments could have a profoun...car winners have been on an average found to live ...t the race and went home and empty-handed. The in...d actresses can be found in the latest issue of th...
...lular biologist who is the principle investigator ...of taste cells would help them to discover molecul...stes.// Researchers from the Monell Chemical Sense...eceptor cells outside the body. They have also bee...
...ly harms the teeth by way of discoloring them, it ...nal treatment, according to a new study // appeari...earch. "The findings substantiate what most of u...o your health," Elizabeth Krall Kaye, PhD, MPH, ep...
...PhD, with the Bradley Hasbro Children's Research C... effect of asthma on children. She said that // th...ving skills may be less likely to have their asthm...inspite of facing the stress related to urban scen...
Other Medicine News:Health News:Oscar Winners Live Longer Than Co-Competitors 2Health News:Functional Taste Cells Cultured In Vitro 2
...mory capabilities for overnight sleep screening.,...turation and pulse rate data, and can operate in t...,1. The Model 130 can retain up to 30 minutes of...ce ideally suited for treadmill or other long-dura...
...d Pulse Oximeter provides SpO 2 and pulse rate mo...evice is battery or AC powered, has adjustable ala...gnals, and an infrared link to a printer (catalog ...for added protection. The digital technology util...
The FingerPrint Pulse Oximeter is a low cost Hand-Held Pulse Oximeter with an integral printer. A light-weight, highly portable device providing SpO 2 and pulse rate measurements, it has easy-to-re
...oring system compatible with personal computers or...d and cost-effective.The BCI 3301 HAND-HELD PULSE ...try wherever spot-checking is needed... including ...spitals. In fact, its ergonomic design, easy-to-re...
Medicine Products: